Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Eligibility Criteria

• * Men and women 18 years of age or older.
• * Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
• * Any histologically confirmed advanced solid tumor with FGFR/FGF pathway alterations including FGFR gene mutations, fusions, and amplifications, as well as gene amplifications of FGFR ligands, who have exhausted or refused approved standard therapies.
• * Evaluable disease according to RECIST v1.1.
• * Men and women 18 years of age or older.
• * Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
• * Histologically confirmed locally advanced/metastatic intrahepatic cholangiocarcinoma with a previously identified FGFR2 gene mutation or rearrangement.
• * Must have received a prior FGFR inhibitor. Participants may have received more than 1 prior FGFR inhibitor.
• * Presence of an FGFR2 kinase domain mutation that confers resistance to previous/other FGFR inhibitors; resistance mutations should be identified by a US Food and Drug Administration authorized/approved companion diagnostic or a Clinical Laboratory Improvement Amendments (CLIA) validated local test performed in a certified laboratory.
• * At least 1 measurable lesion by RECIST v1.1.
• * Discontinued a prior anti-FGFR therapy due to significant toxicity, defined as hepatotoxicity ≥Grade 3 or any Grade 4 toxicity according to CTCAE v5.0.
• * Has a serum phosphorus level \> upper limit of normal (ULN) during screening that remains \>ULN despite medical management.
• * Any ocular condition likely to increase the risk of eye toxicity.
• * History of or current uncontrolled cardiovascular disease.
• * Active, symptomatic, or untreated brain metastases.
• * Gastrointestinal disorders that will affect oral administration or absorption of TYRA-200.
• * Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.